Pharmaceutical giant expects the move will create 3,000 high-skilled jobs and provide work for approximately 10,000 ...

A bevy of major corporations and foreign countries have pledged to pour billions into the U.S. since President Donald Trump ...

Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro, said it will invest an additional ...

China's high-level opening-up has entered a new stage of "two-way empowerment," where foreign-funded firms obtain growth ...

Eli Lilly launched an ad campaign on Friday, cautioning patients against the risks of unapproved weight-loss drugs in its ...

With this latest announcement, Lilly has committed to investing more than $50 billion in U.S. manufacturing since 2020.

The American public lacks transparency regarding the origin of their medications, and the assumption that their drugs come ...

Lilly reckons that the new plants will employ around 3,000 workers, including engineers, scientists, operations personnel, ...

Eli Lilly said Wednesday it will build three manufacturing plants in the United States to make the key raw ingredients in its ...

The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...

Eli Lilly announced plans to invest $27 billion in four new manufacturing sites in the United States. The pharma giant also ...

Eli Lilly and Company (NYSE: LLY) today announced that the National Medical Products Administration (NMPA) in China has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection ...